Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
NCT01808313
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
134
Enrollment
INDUSTRY
Sponsor class
Conditions
Vascular Disease
Interventions
DRUG:
ambrisentan
Sponsor
GlaxoSmithKline